Executive Committee: Indivior PLC

Manager
Positions heldSince
Mark Crossley

Mark Crossley

Chief Executive Officer 28/06/2020
Ryan Preblick

Ryan Preblick

Director of Finance/CFO 28/06/2020
Cynthia Cetani

Cynthia Cetani

Compliance Officer 30/09/2018
Jon Fogle

Jon Fogle

Human Resources Officer 30/09/2014
Christian Heidbreder

Christian Heidbreder

Chief Tech/Sci/R&D Officer 30/11/2014
Kathryn Hudson

Kathryn Hudson

50 year

Public Communications Contact 14/07/2015
Corporate Secretary 14/07/2015
Jeffrey Burris

Jeffrey Burris

52 year

General Counsel 30/11/2021
Jason Thompson

Jason Thompson

Investor Relations Contact -

Composition of the Board of Directors: Indivior PLC

Director
CommitteesSince
Graham Hetherington

Graham Hetherington

65 year

Audit Committee 18/11/2020
Compensation Committee 18/11/2020
Governance Committee Chair 05/05/2021
Nominating Committee Chair 05/05/2021
Joanna Le Couilliard

Joanna Le Couilliard

60 year

Compensation Committee 03/03/2018
Nominating Committee 01/10/2023
Audit Committee Chair 03/03/2018
Compensation Committee Chair 30/09/2023
Nominating Committee Chair 04/02/2019
Audit Committee 23/03/2021
David Wheadon

David Wheadon

66 year

Governance Committee 30/04/2021
Nominating Committee 31/05/2024
Compensation Committee Chair
Audit Committee 30/04/2021
Compensation Committee 31/05/2024
Barbara Ryan

Barbara Ryan

64 year

Audit Committee 26/07/2022
Compensation Committee 31/08/2021
Governance Committee 13/09/2020
Nominating Committee 01/10/2023
Audit Committee Chair 31/08/2021
Juliet Thompson

Juliet Thompson

57 year

Compensation Committee 04/01/2023
Nominating Committee 04/01/2023
Audit Committee Chair 04/01/2023
Governance Committee 23/03/2021
Mark Stejbach

Mark Stejbach

61 year

Audit Committee 23/03/2021
Nominating Committee 01/10/2023
Jerome Lande

Jerome Lande

48 year

Audit Committee 19/12/2015
Finance Committee 19/12/2015
Peter Bains

Peter Bains

66 year

Compensation Committee 26/07/2022
Nominating Committee
Keith Humphreys

Keith Humphreys

Nominating Committee 08/11/2023
Mark Crossley

Mark Crossley

Executive Committee 20/02/2017
Ryan Preblick

Ryan Preblick

Director/Board Member 19/11/2020

Former Officers and Directors: Indivior PLC

Insider
Positions held
SinceUntil
A. McLellan
A. McLellan
Director/Board Member 03/11/2014 28/02/2024
Independent Dir/Board Member 03/11/2014 28/02/2024
Daniel Phelan
Daniel Phelan
Director/Board Member 03/11/2014 29/09/2023
Independent Dir/Board Member 03/11/2014 29/09/2023
Lorna Parker
Lorna Parker
Director/Board Member 03/11/2014 29/09/2023
Independent Dir/Board Member 03/11/2014 29/09/2023
Nina DeLorenzo
Nina DeLorenzo
Corporate Officer/Principal 15/06/2022 -
Susan Learned
Susan Learned
Corporate Officer/Principal 31/07/2015 30/06/2021
Daniel Tassé
Daniel Tassé
Director/Board Member 18/11/2020 05/05/2021
Chairman 14/06/2020 18/11/2020
Independent Dir/Board Member 18/11/2020 05/05/2021
Javier Rodriguez
Javier Rodriguez
General Counsel 30/11/2014 30/11/2020
Rosh Dias
Rosh Dias
Chief Tech/Sci/R&D Officer 31/10/2019 31/07/2020
Tatjana Anni Hilde May
Tatjana Anni Hilde May
Director/Board Member 31/01/2017 30/07/2020
Independent Dir/Board Member 31/01/2017 30/07/2020
Shaun Thaxter
Shaun Thaxter
Director/Board Member 03/11/2014 28/06/2020
Chief Executive Officer 03/11/2014 28/06/2020
Howard H. Pien
Howard H. Pien
Chairman 03/11/2014 14/06/2020
Frank Stier
Frank Stier
Corporate Officer/Principal 30/09/2014 31/01/2020
Lizabeth Zlatkus
Lizabeth Zlatkus
Director/Board Member 31/08/2016 30/08/2019
Independent Dir/Board Member 31/08/2016 30/08/2019
Christian Schade
Christian Schade
Director/Board Member 03/11/2014 30/07/2019
Independent Dir/Board Member 03/11/2014 30/07/2019
Ponni Subbiah
Ponni Subbiah
Chief Tech/Sci/R&D Officer 30/09/2016 31/03/2019
Michael R. Clarke
Michael R. Clarke
Compliance Officer - 31/03/2019
Yvonne Greenstreet
Yvonne Greenstreet
Director/Board Member 03/11/2014 30/03/2019
Independent Dir/Board Member 03/11/2014 30/03/2019
Ingo Elfering
Ingo Elfering
Chief Tech/Sci/R&D Officer 31/10/2014 31/08/2018
Cary Claiborne
Cary Claiborne
Director/Board Member 13/11/2014 06/03/2017
Director of Finance/CFO 13/11/2014 02/02/2017
Tony Goodman
Tony Goodman
Corporate Officer/Principal 30/09/2014 31/01/2017
Rupert Bondy
Rupert Bondy
Director/Board Member 03/11/2014 29/09/2016
Independent Dir/Board Member 03/11/2014 29/09/2016
Adrian Hennah
Adrian Hennah
Director/Board Member 03/11/2014 10/05/2016
Timothy Baxter
Timothy Baxter
Chief Tech/Sci/R&D Officer 30/09/2014 30/04/2016
Alex Lugovoy
Alex Lugovoy
Corporate Officer/Principal - -
Lola Emetulu
Lola Emetulu
Corporate Secretary - -
Tom Corran
Tom Corran
Investor Relations Contact - -
Debby Betz
Debby Betz
Public Communications Contact 30/09/2014 -
Andraea Dawson-Shepherd
Andraea Dawson-Shepherd
Public Communications Contact - -
Richard F. Joyce
Richard F. Joyce
Investor Relations Contact - -
Murali Gopal
Murali Gopal
Chief Tech/Sci/R&D Officer - -

Age distribution of managers

Parity Men Women

Male 16
Female 6

Of which Executive Committee

Male 6
Female 2

Of which Directors

Male 8
Female 3
ESG Refinitiv
B

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy
Logo Indivior PLC
Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
Employees
1,000
More about the company

Departures of Key Persons

Howard H. Pien
-
Howard H. Pien

Chairman

03/11/2014 14/06/2020

Shaun Thaxter
-
Shaun Thaxter

Chief Executive Officer

03/11/2014 28/06/2020

Daniel Tassé
-
Daniel Tassé

Chairman

14/06/2020 18/11/2020

-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities. Last hours!
BENEFIT NOW